<DOC>
	<DOCNO>NCT00216151</DOCNO>
	<brief_summary>Evidence beneficial effect bisphosphonates bone resorption multiple myeloma report extensively , show reduction skeletal event improvement several biochemical variable bone resorption . Zoledronic acid ( ZometaÂ® , CGP42446 ) potent clinically available bisphosphonates , large therapeutic ratio desire inhibition calcium resorption unwanted inhibition mineralization vitro bisphosphonates . This trial investigate efficacy zoledronic acid prevent skeletal event patient asymptomatic/early stage Multiple Myeloma</brief_summary>
	<brief_title>Zoledronic Acid Management Patients With Asymptomatic/Early Stage Multiple Myeloma</brief_title>
	<detailed_description>OUTLINE : This multi-center study . - Patients randomly assign study number receive 4mg zoledronic acid every three month observe . Performance status : ECOG performance status 0-3 ( KPS 30 - 100 ) Life expectancy : 12 month Hematopoietic : - Hb &gt; 10 g/dl within 14 day prior registration Hepatic : - Not specify Renal : - Serum creatinine &lt; 2 mg/dl within 14 day prior registration Cardiovascular : - Not specify Pulmonary : - Not specify</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Diagnosis asymptomatic multiple myeloma define criterion : Presence bone marrow clonal plasma cell ( 10 % ) Presence Mprotein serum and/or urine ( concentration specify ) Serum calcium &lt; 12 mg/dl within 14 day prior registration . Less 3 lytic lesion , pathologic fracture osteopenia note skeletal survey No symptom hyperviscosity , amyloidosis recurrent infection Bone mineral density T score high 2.0 standard deviation ( osteoporosis ) within 28 day prior registration Negative pregnancy test No previous treatment bisphosphonates No disorder parathyroid thyroid glands No current breastfeeding No prior malignancy allow except adequately treat situ cervical cancer , Gleason &lt; grade 7 prostate cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Bisphosphonates</keyword>
</DOC>